Steve Silver

KCSA Strategic Communications

Recent Quotes

"PMN expects to file an NDA for PMN310 with the FDA by 2022E."

— Steve Silver, Argus Research (10/28/22)
more >

more quotes

"PMN designated PMN267 as its lead candidate for treatment of ALS."

— Steve Silver, Argus Research (7/6/22)
more >

"PMN's PMN310 potentially represents a best-in-class opportunity."

— Steve Silver, Argus Research (6/27/22)
more >

fewer comments


Due to permission requirements, not all quotes are shown.